DHW-221
DHW-221 is a potent orally active dual PI3K/mTOR inhibitor, exhibiting low nanomolar potency against all four Class I PI3K isoforms and mTOR (PI3Kα, IC50 = 0.50 nM; PI3Kβ, IC50 = 1.9 nM; PI3Kγ, IC50 = 1.8 nM; PI3Kδ, IC50 = 0.74 nM; mTOR, IC50 = 3.9 nM). DHW-221 exerts antitumor effects by blocking the PI3K/Akt/mTOR pathway and inducing mitochondrial apoptosis and paraptosis (via Endoplasmic Reticulum (ER) stress and MAPK signaling) and arrests cell cycle, thereby inhibiting cell migration, invasion and angiogenesis. DHW-221 inhibits tumor growth in both the A549/Taxol (HY-B0015) and the HCC827 xenograft mouse models. DHW-221 can be used for non-small cell lung cancer (NSCLC), colon and breast cancer research.
For research use only. We do not sell to patients.
- CAS No.: 2378831-21-9
- Formula: C27H22F2N4O5S
- Molecular Weight:552.55
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
All VEGFR Isoforms
More
Biological Activity
Description
IC50 & Target
[1]|
PI3Kα 0.50 nM (IC50) |
PI3Kβ 1.9 nM (IC50) |
PI3Kδ 0.74 nM (IC50) |
PI3Kγ 1.8 nM (IC50) |
mTOR 3.9 nM (IC50) |
In Vitro
DHW-221 (compound 8i) (72 h) shows antiproliferation activity against typically human cancer cells with IC50 values of 0.36 μM (T47D), 0.14 μM (HCT116), and 0.31 μM (MCF-7)[1].
DHW-221 (0.3-3 μM) decreases the phospho-Akt (S473) in a dose-dependent manner in HCT116 cells with no significant change in the expression of total protein Akt[1].
DHW-221 (0-5 μM, 2 weeks) inhibits the proliferation of HCT116 cells in a dose-dependent manner[1].
DHW-221 (0.3-3 μM, 0-48 h) inhibits HCT116 cell metastasis and invasiveness in a dose-dependent manner[1].
DHW-221 (0.3-3 μM) induces apoptosis in HCT116 cells in a concentration-dependent manner, with marked nuclear fragmentation and condensation of chromatin[1].
DHW-221 fits into the binding site of PI3K kinase similarly to Omipalisib (HY-10297), forming hydrogen bonds with Val882, Lys833, and Thr887, as well as Pi-Pi interactions with multiple amino acid residues[1].
DHW-221 (72 h) exhibits significant cytotoxicity in a concentration- and time-dependent manner in A549/Taxol (IC50 = 0.5274 μM) and A549 cells (IC50 = 0.4242 μM)[2].
DHW-221 (0-2.4 μM, 48-72 h) exerts significant inhibitory activity in MDR cancer cells (A549 and A549/Taxol cells), resulting in severe cellular damage at 48 h compared to control group in both cells[2].
DHW-221 (0.15-2.4 μM, 48 h) increases intracellular Rho-123 accumulation in a concentration-dependent manner in A549/Taxol cells and significantly downregulates P-gp expression, indicating that it inhibits P-gp function and protein expression[2].
DHW-221 (50 nM, 48 h) significantly enhances the cytotoxic effect of Taxol, an effect similar to the P-gp inhibitor Verapamil (HY-14275), suggesting that it functions as a P-gp inhibitor and a MDR reversal agent[2].
DHW-221 (0.15-2.4 μM, 12-48 h) triggers apoptosis and paraptosis in A549/Taxol cells through the mitochondrial pathway, ER stress and the MAPK signaling pathway[2].
DHW-221 (0.15-2.4 μM, 48 h) arrests the cell cycle at the G0/G1 phase in A549/Taxol and A549 cells by downregulating cyclin D1, CDK4, and CDK6, and upregulating p21[2].
DHW-221 (0.05-0.15 μM, 48 h) suppresses the migration and invasion capabilities of A549/Taxol cells through reversing epithelial-mesenchymal transition (EMT) phenotypic changes[2].
DHW-221 (0.15-2.4 μM, 48 h) significantly blocks the PI3K/Akt signaling pathway in both A549 and A549/Taxol cells, as demonstrated by decreased levels of PI3Kp110α and phosphorylated Akt (p-Akt)[2].
DHW-221 (25-400 nM, 1-3 h) inhibits endothelial tube formation in Human Umbilical Vein Endothelial Cells (HUVECs) by suppressing the PI3K/HIF-1α/VEGF signaling axis[3].
DHW-221 (1.56-6.25 µM) inhibits microvessel sprouting in rat aortic ring assays ex vivo[3].
DHW-221 (1.25-5 µM) inhibits neovascularization in chick chorioallantoic membranes without affecting embryo viability[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:HCT116 cells
-
Concentration:0.3, 1 and 3 μM
-
Incubation Time:2 weeks
-
Result:Inhibited the formation of HCT116 cell clones in a concentration-dependent manner.
Almost completely inhibited the production of cell clones at 3 μM.
-
Cell Line:HCT116 cells
-
Concentration:0.3, 1 and 3 μM
-
Incubation Time:0, 24 and 48 h
-
Result:Its inhibition ability increased in a concentration-dependent manner.
-
Cell Line:HCT116 cells
-
Concentration:0.3, 1 and 3 μM
-
Incubation Time:48 h
-
Result:Significantly inhibited HCT116 cell metastasis and invasiveness in a dose-dependent manner.
-
Cell Line:A549 and A549/Taxol cells
-
Concentration:0.075, 0.15, 0.3, 0.5, 1.2 and 2.4 μM
-
Incubation Time:24, 48 and 72 h
-
Result:Exhibited significant cytotoxicity in a concentration- and time-dependent manner in A549/Taxol and A549 cells with an resistance index (RI) of 1.2.
-
Cell Line:A549 and A549/Taxol cells
-
Concentration:0.15, 0.60 and 2.40 μM
-
Incubation Time:2 weeks
-
Result:Decreased the colony formation ability of A549/Taxol and A549 cells in a concentration-dependent manner.
-
Cell Line:A549 and A549/Taxol cells
-
Concentration:0.15, 0.60 and 2.40 μM
-
Incubation Time:48 h
-
Result:Increased LDH release rates in A549 and A549/Taxol cells in a concentration-dependent manner.
-
Cell Line:A549 and A549/Taxol cells
-
Concentration:0.15, 0.60 and 2.40 μM
-
Incubation Time:3, 6, 12, 24 and 48 h
-
Result:Upregulated the expression levels of apoptosis-related proteins (cytochrome C, cleaved caspase 3, and cleaved PARP) in A549/Taxol cells in a concentration-dependent manner.
Downregulated the expression levels of the anti-apoptotic protein, Bcl-2, in A549/Taxol cells in a concentration-dependent manner.
Significantly inhibited the expression of Alix in A549/Taxol cells.
Significantly upregulated the expression levels of ATF4, CHOP (key regulator in ER stress), p-JNK, p-ERK, and p-p38 in A549/Taxol cells.
Decreased the expression levels of cyclin D1, CDK4, and CDK6 and increased p21 levels in A549/Taxol cells in a concentration-dependent manner.
Significantly decreased the expression levels of PI3Kp110a and p-Akt in a concentration-dependent manner, with no obvious change in the total Akt level in both cells.
Blocked the PI3K/Akt signaling pathway in both A549/Taxol and A549 cells.
Significantly downregulated p-FOXO3a (Ser253) expression and upregulated FOXO3a expression, accompanied by an increase in Bim expression in A549/Taxol cells.
Showed no significant changes in FOXO3a and Bim expression levels were observed in A549 cells.
Promoted FOXO3a accumulation in A549/Taxol cells when combined with MG132 (HY-13259).
Interfered with FOXO3a degradation in a proteasome-independent manner.
-
Cell Line:A549/Taxol cells
-
Concentration:0.15, 0.60 and 2.40 μM
-
Incubation Time:24 and 48 h
-
Result:Increased nuclear FOXO3a protein and decreased cytoplasmic phosphorylated FOXO3a at the Ser253 site.
Reversed the EMT phenotype, evidenced by enhanced fluorescence intensity of the epithelial marker occludin and weakened fluorescence of the mesenchymal marker vimentin.
-
Cell Line:A549 and A549/Taxol cells
-
Concentration:0.15, 0.60 and 2.40 μM
-
Incubation Time:12 h (for vacuolation), and 48 h (for apoptosis/MMP)
-
Result:Significantly increased the rates of early and late apoptosis in both A549/Taxol and A549 cells after 48 h.
Its pro-apoptotic ability in A549/Taxol cell was stronger than that of A549 cells at 2.4 μM.
Triggered apoptosis in A549/Taxol and A549 cells in a concentration-dependent manner.
Decreased the intracellular MMP in A549/Taxol cells after 48 h.
Induced the formation of massive vacuoles in A549/Taxol cells at 2.4 μM after 12 h.
Attenuated cytoplasmic vacuolation when combined with Cycloheximide (HY-12320, 20 μM).
-
Cell Line:A549/Taxol cells
-
Concentration:0.15, 0.60 and 2.40 μM
-
Incubation Time:48 h
-
Result:Significantly reduced the proportion of cells in S phase and increased the proportion of cells in G0/G1 phase.
-
Cell Line:A549 and A549/Taxol cells
-
Concentration:0.05, 0.10 and 0.15 μM
-
Incubation Time:0, 24 and 48 h
-
Result:Significantly decreased the wound healing rate compared to the control group in both A549 and A549/Taxol cells.
-
Cell Line:A549 and A549/Taxol cells
-
Concentration:0.05, 0.10 and 0.15 μM
-
Incubation Time:24 h
-
Result:Significantly reduced the number of cells that migrated and invaded through the chamber in A549/Taxol cells.
-
Cell Line:A549/Taxol cells
-
Concentration:0.05, 0.10 and 0.15 μM
-
Incubation Time:48 h
-
Result:Increased the expression levels of E-cadherin and occludin but significantly decreased the expression levels of mesenchymal markers, including vimentin and slug.
Decreased the expression of transcription factor snail.
Significantly downregulated the expression levels of MMP2 and MMP9 in A549/Taxol cells.
Parmacokinetics
In Vivo
DHW-221 (10, 20, and 40 mg/kg, p.o., q.d. for 21 days) inhibits tumor growth in HCC827 xenograft mice model[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Male nude mice (4-6 weeks old) intravenously injected with A549/Taxol cells[2]
-
Dosage:25 and 50 mg/kg
-
Administration:i.g., q.d. for 2 weeks
-
Result:Significantly decreased the number of lung nodules.
Downregulated p-FOXO3a expression and upregulated FOXO3a expression.
Showed no change in Ki67 expression.
Showed no significant differences in the body weight and viscera index compared to the control group.
Caused no behavioral abnormalities or loss of appetite.
Exhibited no evident histological abnormalities in the heart, liver, kidney, or spleen.
Resulted in no abnormal toxicity signs in serum biochemical parameters (CK, ALT, AST, CRE), indicating no cardiac, hepatic, or renal toxicity.
-
Animal Model:Nude mice bearing HCC827 xenografts (Subcutaneous and orthotopic injection)[3]
-
Dosage:10, 20 and 40 mg/kg
-
Administration:p.o., q.d. for 21 days
-
Result:Significantly inhibited tumor growth in both subcutaneous and orthotopic models.
Showed no significant effect on body weight.
Exhibited only mild liver toxicity at the high dose (40 mg/kg).
Chemical Information
-
CAS No. 2378831-21-9
-
Molecular Weight 552.55
-
Formula C27H22F2N4O5S
-
SMILES
O=S(C1=CC=C(F)C=C1F)(NC2=CC(C3=CC=C4C(N(C5=CC=C(OCCO)C=C5)C=N4)=C3)=CN=C2OC)=O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Human pluripotent stem cell endothelial-cell differentiation
Human pluripotent stem cell endothelial differentiation is based on stepwise developmental patterning: early activation of WNT/GSK3β inhibition promotes mesodermal or vascular progenitor entry, followed by endothelial specification using VEGF-related signaling, BMP4, FGF2, Notch modulation, or cAMP depending on the published protocol. Endothelial differentiation is read out by acquisition of CD31, CD34, VE-cadherin/CD144, KDR/VEGFR2, vWF, Tie2, NOS3, acetylated LDL uptake, tube/network formation, barrier function, and in vivo vessel-forming capacity where tested.
-
Cell migration
Cell migration is a method that plays an important role in wound healing, cell differentiation, embryonic development, etc.
-
Breast Cancer Modeling
Breast cancer is a heterogeneous cancer, and it has been distinguished into four subtypes: luminal A, luminal B, HER2-positive and basal-like. Molecular mutations, epigenetic alterations, hormone exposure and immune microenvironment are related to the progression of breast cancer.
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Flow cytometric DNA-content cell-cycle staining
Flow cytometric DNA-content cell-cycle staining measures the fluorescence intensity of DNA-bound fluorochromes in single cells or nuclei to estimate DNA content distributions, allowing assignment of populations to G0/G1, S, and G2/M phases by DNA histogram deconvolution. Propidium iodide (PI) intercalates into DNA, and PI fluorescence is proportional to cellular DNA content when staining is performed under conditions that make DNA accessible and minimize non-DNA signal. Cells with G2/M DNA content are expected to show approximately twice the fluorescence intensity of G0/G1 cells, while S-phase cells occupy intermediate fluorescence values. PI-based DNA-content analysis can also detect cells with fractional DNA content, often reported as sub-G1, when DNA fragmentation and extraction during staining reduce retained DNA signal in apoptotic cells. DAPI is an alternative DNA fluorochrome for univariate DNA-content analysis, while bivariate approaches combining DNA content with proliferation
-
Chemotaxis Gradient Chamber Assay 1
The chemotaxis gradient chamber assay is based on the principle of observing directional cell migration in response to a stable, linear or quasi-linear concentration gradient of a chemoattractant formed between two fluid reservoirs separated by a narrow observation chamber. Cells placed within the chamber respond to the gradient by polarized movement toward higher chemoattractant concentrations, allowing quantification of chemotactic behavior in real time under microscopy. The classic Zigmond chamber design enables simultaneous visualization of gradient formation and individual cell trajectories, making it suitable for studying leukocyte chemotaxis and other motile cell types in vitro.
-
Under-Agarose Cell Migration Assay
The under-agarose cell migration assay is a classical in vitro chemotaxis method designed to evaluate directed cell movement through a semi-solid agarose matrix toward soluble chemoattractant gradients, enabling visualization and quantification of leukocyte or motile cell migration in a confined 2D-like environment. In this system, cells and chemoattractants are placed in separate wells cut into an agarose gel, allowing diffusion-driven gradient formation that guides directional migration, which is typically assessed by measuring migration distance, cell morphology changes, and accumulation toward the chemoattractant source. This assay has been widely used to study neutrophil and leukocyte chemotaxis as a simple alternative to filter-based migration systems and allows direct microscopic observation of migrating cells under near-physiological confinement conditions.
-
Transwell/Boyden Chamber Migration Assay
The Transwell/Boyden chamber migration assay measures cell movement through a porous membrane separating an upper and lower chamber, usually after a chemoattractant gradient is established by placing cells in the upper chamber and chemoattractant-containing medium in the lower chamber. The readout is generated by quantifying cells that traverse the membrane and appear on the lower membrane surface or in the lower chamber, depending on whether the cell type is adherent or non-adherent. This assay reflects chemotactic or haptotactic migration rather than matrix invasion unless an extracellular-matrix barrier is added to the membrane.
-
Endothelial Tube Formation Assay
Endothelial tube formation assay evaluates the ability of endothelial cells to attach, migrate, align, and organize into capillary-like networks when cultured on gelled basement membrane extract or Matrigel; the readout is the morphology and quantity of tube-like networks, which reflects an in vitro endothelial morphogenesis step related to angiogenesis. Basement membrane extract/Matrigel provides laminin-rich extracellular matrix cues that support endothelial differentiation into capillary-like structures, but it can contain biologically active growth factors, so growth-factor-reduced matrix is preferred when testing defined angiogenic stimulators or inhibitors.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
3D Collagen/Hydrogel Matrix Migration Assay
The 3D collagen/hydrogel matrix migration assay is based on embedding cells within or on top of a fibrillar collagen type I-rich three-dimensional matrix to model in vivo-like extracellular matrix (ECM) architecture, enabling analysis of cell migration through a physically and biochemically relevant scaffold. In contrast to 2D migration systems, cells in 3D matrices interact with fibrillar collagen networks, requiring coordinated adhesion remodeling and proteolytic or non-proteolytic deformation mechanisms to move through confined spaces, thereby providing a more physiologically relevant readout of invasive and migratory behavior in tissue-like environments. Cell movement in 3D collagen matrices is typically quantified by tracking single-cell trajectories, invasion depth, or matrix penetration over time, reflecting combined effects of cytoskeletal dynamics, cell-ECM adhesion turnover, and ECM remodeling. These systems are widely used to study tumor cell invasion and stromal cell motili
-
Cell invasion
Cell invasion is the ability of cells to migrate from one area to another via the extracellular matrix. Cell invasion is the response of normal and cancer cells to chemical and mechanical stimuli. Before migrating to a new region, the extracellular matrix is degraded by proteases within the cell. Cell invasion often occurs during wound repair, vascularization and inflammation, abnormal tissue invasion, and tumor cell metastasis.
-
Cell-Exclusion Zone Migration Assay
The Cell-Exclusion Zone (CEZ) migration assay is an in vitro 2D cell migration method in which a defined cell-free area is created using removable physical barriers such as silicone stoppers, allowing cells to be seeded around the barrier and subsequently migrate into the cleared zone after barrier removal. This approach enables quantification of collective cell migration by monitoring repopulation of the initially cell-free region over time using microscopy-based imaging. Compared with scratch-based wound healing assays, barrier-based exclusion methods are designed to avoid mechanical damage to the extracellular matrix and reduce injury-induced effects on boundary cells, thereby improving interpretability of migration behavior in vitro. The assay readout is typically the progressive reduction in the cell-free area or the number of cells invading the exclusion zone, reflecting coordinated cell motility relevant to physiological processes such as wound healing, epithelial repair, and ca
-
Chemotaxis Gradient Chamber Assay 2
Chemotaxis gradient chamber assays measure directional cell migration in response to a soluble chemical gradient by imaging cells as they move across a defined observation region; the readout is generated from time-lapse cell trajectories, displacement toward the gradient, forward migration index, trajectory plots, rose/polar plots, and statistical tests of non-random directionality. The Dunn chamber is a direct-viewing glass chamber in which cells migrate across a bridge between control and chemoattractant wells, allowing observation of cells in a linear concentration gradient; related direct-viewing formats include the Insall chamber, which supports defined unidirectional gradients and high numerical-aperture microscopy, and the μ-Slide Chemotaxis chamber, which supports long-term live-cell imaging and gradient characterization with fluorescent dye.
-
Endothelial Cell Migration/Angiogenic Sprouting Assay
Endothelial cell migration and angiogenic sprouting assays are in vitro (and partially ex vivo-adapted) functional models that quantify the ability of endothelial cells to undergo coordinated migration, extracellular matrix invasion, and multicellular organization into capillary-like sprouts in response to pro-angiogenic stimuli such as VEGF, bFGF, or conditioned microenvironments. These assays are used to model early angiogenic events including tip-cell formation, directional migration, and lumen-like sprout extension, which collectively reflect angiogenic activation and vascular morphogenesis processes observed in vivo.
-
Scratch/Wound-Healing Migration Assay
The scratch/wound-healing migration assay measures collective migration of adherent cells into an experimentally created cell-free gap in a confluent monolayer. The readout is generated by imaging the gap immediately after scratching and at later time points, then quantifying reduction in wound area, wound width, or percentage closure as cells move into the denuded region. Gap closure reflects cell migration but may also include cell proliferation, so interpretation should distinguish migration-focused conditions from proliferation-driven closure when possible, such as by using short assay windows, serum-controlled conditions, cell counting, or proliferation controls reported in published protocols.
-
Vascular/Branching Fractal Analysis
Vascular/branching fractal analysis quantifies the geometric complexity of vessel trees or vascular networks from segmented 2D images, commonly by converting vessels into binary and/or skeletonized maps and estimating fractal dimension using box-counting or related approaches. Fractal dimension is interpreted as an image-derived readout of vascular branching complexity, space filling, or density, and has been applied to retinal photographs, fluorescein angiography, OCT angiography, capillary perfusion maps, and in vitro Matrigel angiogenesis networks. The assay readout is generated from vessel-positive pixels after image preprocessing, vessel segmentation, binarization, and optional skeletonization; reported outputs include fractal dimension, vessel density, branchpoint density, endpoint density, vessel length density, tortuosity, and generation-based branching metrics when VESGEN-style analysis is used. The biological interpretation is limited to quantitative vascular patterning and s
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
BrdU Incorporation Assay
Bromodeoxyuridine (BrdU) incorporation assay is based on the principle that BrdU, a thymidine analog, is incorporated into newly synthesized DNA during the S phase of the cell cycle, thereby serving as a marker of DNA replication and cellular proliferation. Incorporated BrdU can be detected using anti-BrdU antibodies following DNA denaturation, enabling visualization or quantification of proliferating cells through immunochemical detection methods such as immunofluorescence or immunohistochemistry.
-
Neural Crest/Neuronal Cell Migration Explant Assay
Neural crest (NC) and neuronal cell migration explant assays are in vitro systems in which neural tube-derived tissues are cultured to allow premigratory or newly emigrated neural crest cells to undergo epithelial-to-mesenchymal transition (EMT), migrate away from the explant, and form a measurable radial outgrowth that reflects migratory capacity and environmental responsiveness. These assays typically quantify migration by measuring the expansion of cell outgrowth from neural tube or neural plate border explants over time, often comparing early and later timepoints to derive a migration index such as a radius ratio, which reflects net cell dispersal from the explant core. Neural tube explant cultures preserve key aspects of neural crest behavior, including EMT, migration, and early differentiation, making them suitable for assessing intrinsic migratory ability and extrinsic cue dependence. However, studies emphasize that migratory outgrowth from neural tube explants may include non-n
-
Patient-Derived Orthotopic Xenograft (PDOX)
Patient-derived orthotopic xenograft (PDOX) modeling implants fresh patient tumor tissue or patient-derived tumor cells into the anatomically corresponding organ or tissue site of immunodeficient mice, usually by surgical orthotopic implantation, to preserve patient tumor histology, local microenvironmental context, invasion, metastatic behavior, and treatment-response features better than subcutaneous implantation. PDOX readouts include tumor engraftment, orthotopic tumor growth, local invasion, metastasis, recurrence after resection, histologic similarity to the donor tumor, biomarker retention, molecular concordance, survival, and response or resistance to therapy. PDOX models are used for preclinical drug testing and individualized therapy evaluation, but engraftment success varies by tumor type and specimen quality.
-
Protocol for Cell Cycle
Cell-cycle analysis by flow cytometry measures DNA content in single cells to estimate the fraction of cells in G0/G1, S, and G2/M phases. Propidium iodide intercalates into DNA, and after RNA removal with RNase, fluorescence intensity reflects cellular DNA content: 2N cells are assigned to G0/G1, cells between 2N and 4N to S phase, and 4N cells to G2/M. DNA-content analysis alone cannot reliably separate G0 from G1 or G2 from M. Ki-67 can distinguish quiescent G0 cells from cycling cells, EdU or BrdU incorporation marks active DNA synthesis in S phase, and phospho-histone H3 staining identifies mitotic cells within the 4N population.
-
Patient-Derived Xenograft (PDX)
Patient-derived xenograft (PDX) models are generated by engrafting primary human tumor tissue directly into immunodeficient mice, allowing in vivo propagation of patient tumor biology without initial in vitro adaptation. These models are used to preserve key histopathological and molecular characteristics of the original tumor and enable assessment of tumor growth dynamics and therapeutic response in a living organism. The biological readout is tumor engraftment and subsequent growth in the murine host, which reflects the ability of human tumor cells to survive, vascularize, and expand in an immunocompromised microenvironment.
-
Splenic/Portal-Vein Liver Metastasis Xenograft
Splenic and portal-vein liver metastasis xenograft models deliver tumor cells into the portal circulation so that cells reach the liver first and form hepatic metastatic lesions; splenic injection uses the spleen as an access route to the portal system, while direct portal-vein injection introduces cells into the portal vein without requiring splenectomy. The assay detects liver colonization, intrahepatic tumor growth, tumor distribution, treatment response, survival, and liver-metastasis microenvironment changes; readouts include bioluminescence or fluorescence imaging, gross liver nodule counts, liver weight or tumor burden, histology, and survival.
-
Subcutaneous Cell-Line-Derived Xenograft
Subcutaneous cell-line-derived xenograft (CDX) models are established by implanting cultured human cancer cell lines into immunodeficient mice, where the injected cells form localized tumors that can be monitored in vivo as a measure of tumorigenic potential, growth kinetics, and treatment response. These models are widely used in oncology research because they allow reproducible tumor formation and enable comparative assessment of tumor growth between different cell lines or genetic manipulations in a controlled in vivo microenvironment. Subcutaneous implantation of cancer cells in immunodeficient mice is a standard approach for evaluating tumor growth behavior and therapeutic response across multiple cancer types, including prostate, esophageal, pancreatic, and colon cancer models.
-
Orthotopic Cell-Line Xenograft
Orthotopic cell-line xenograft models involve implantation of human cancer cell lines into the anatomically corresponding organ of immunodeficient mice to reproduce tumor growth within a native microenvironment, enabling more clinically relevant tumor behavior compared with subcutaneous models. These models are widely used because orthotopic placement better recapitulates tumor progression, including invasion and metastatic spread, which are often underrepresented in heterotopic implantation systems. Compared with conventional xenografts, orthotopic implantation is described as more technically complex but provides improved simulation of tumor-microenvironment interactions and metastatic behavior, making it particularly valuable for translational oncology research. Surgical orthotopic implantation approaches have been emphasized as enabling faithful reproduction of clinical cancer features, including metastasis and disease progression patterns that align with the tumor’s organ of origi
-
Intraperitoneal/Peritoneal Dissemination Xenograft
Intraperitoneal (IP) or peritoneal dissemination xenograft models are based on the introduction of human cancer cells into the peritoneal cavity of immunodeficient mice, where they attach to peritoneal surfaces, form multicellular aggregates or spheroids, and progressively generate disseminated tumor nodules that mimic advanced peritoneal metastatic disease. These models are widely used to study ovarian cancer progression, tumor-microenvironment interactions, and intraperitoneal therapeutic responses, often incorporating bioluminescence or fluorescence imaging to longitudinally monitor tumor burden in vivo. The biological principle relies on the capacity of tumor cells such as SKOV3 or related ovarian carcinoma lines to survive in suspension, aggregate within ascites-like fluid, adhere to mesothelial surfaces, and invade peritoneal organs, thereby recapitulating human peritoneal carcinomatosis patterns observed in advanced disease.
Purity & Documentation
References
[1]. Ding HW, et al. Design, synthesis, and biological evaluation of some novel 4-aminoquinazolines as Pan-PI3K inhibitors. Bioorg Med Chem. 2019 Jul 1;27(13):2729-2740. [Content Brief]
[2]. Liu M, et al. DHW-221, a Dual PI3K/mTOR Inhibitor, Overcomes Multidrug Resistance by Targeting P-Glycoprotein (P-gp/ABCB1) and Akt-Mediated FOXO3a Nuclear Translocation in Non-small Cell Lung Cancer. Front Oncol. 2022 May 13;12:873649. [Content Brief]
[3]. Qin X, et al. Dual blocking of PI3K and mTOR signaling by DHW-221, a novel benzimidazole derivative, exerts antitumor activity in human non-small cell lung cancer. Clin Transl Med. 2021 Sep;11(9):e514. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)